Gastrointestinal cancers: new standards of care from landmark trials | MDedge Hematology and Oncology
HER2 Status in Colorectal Cancer: Its Clinical Significance and the Relationship between HER2 Gene Amplification and Expression | PLOS ONE
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study | Modern Pathology
Frontiers | Human Epidermal Growth Factor Receptor 2 Overexpression and Amplification in Patients With Colorectal Cancer: A Large-Scale Retrospective Study in Chinese Population
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial - The Lancet Oncology
ESMO 2019 Highlights in metastatic colorectal cancer: The HERACLES-B study - YouTube
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study | Modern Pathology
Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial | Nature Medicine
Dual HER2 Blockade in Patients With HER2-Amplified Metastatic
Gastrointestinal cancers: new standards of care from landmark trials | MDedge Hematology and Oncology
PDF) Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: The phase II HERACLES-B trial
HER2 in Colorectal Carcinoma - Surgical Pathology Clinics
![PDF] Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/902d0b938fec74e846b6e114a899720dcadb2ead/34-Figure2-1.png "PDF] Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. | Semantic Scholar")
PDF] Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. | Semantic Scholar
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial - ESMO Open
Update systemic therapy in solid tumor
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial - ESMO Open
![PDF] Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/902d0b938fec74e846b6e114a899720dcadb2ead/33-Figure1-1.png "PDF] Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. | Semantic Scholar")
PDF] Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. | Semantic Scholar
Human Epidermal Growth Factor Receptor 2–Targeting Approaches for Colorectal Cancer: Clinical Implications of Novel Treatments and Future Therapeutic Avenues | JCO Oncology Practice
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer - Annals of Oncology
THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES - ppt download
Molecular Testing to Optimize and Personalize Decision Making in the Management of Colorectal Cancer
Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer
![HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China [PeerJ]](https://dfzljdn9uc3pi.cloudfront.net/2020/8602/1/fig-1-full.png "HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China [PeerJ]")
HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China [PeerJ]
